| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue Engineering | 115 | 2021 | 700 | 12.760 |
Why?
|
| Tissue Scaffolds | 65 | 2021 | 435 | 7.680 |
Why?
|
| Kidney | 21 | 2021 | 528 | 5.000 |
Why?
|
| Stem Cells | 30 | 2020 | 331 | 3.780 |
Why?
|
| Animals | 160 | 2020 | 8579 | 3.540 |
Why?
|
| Collagen | 32 | 2021 | 240 | 2.820 |
Why?
|
| Regenerative Medicine | 17 | 2019 | 219 | 2.800 |
Why?
|
| Extracellular Matrix | 22 | 2020 | 261 | 2.760 |
Why?
|
| Amniotic Fluid | 19 | 2019 | 86 | 2.710 |
Why?
|
| Muscle, Skeletal | 20 | 2020 | 575 | 2.540 |
Why?
|
| Regeneration | 20 | 2019 | 179 | 2.390 |
Why?
|
| Biocompatible Materials | 29 | 2018 | 242 | 2.390 |
Why?
|
| Stem Cell Transplantation | 20 | 2020 | 229 | 2.190 |
Why?
|
| Cells, Cultured | 49 | 2020 | 889 | 2.020 |
Why?
|
| Mice | 51 | 2020 | 2720 | 1.760 |
Why?
|
| Muscle Fibers, Skeletal | 15 | 2020 | 115 | 1.670 |
Why?
|
| Endothelial Cells | 16 | 2020 | 204 | 1.650 |
Why?
|
| Cell Proliferation | 26 | 2020 | 633 | 1.630 |
Why?
|
| Polyesters | 14 | 2016 | 78 | 1.630 |
Why?
|
| Blood Vessels | 5 | 2018 | 60 | 1.620 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2020 | 302 | 1.550 |
Why?
|
| Rats | 36 | 2020 | 1946 | 1.540 |
Why?
|
| Urethra | 17 | 2016 | 125 | 1.530 |
Why?
|
| Reperfusion Injury | 5 | 2020 | 60 | 1.520 |
Why?
|
| Colon | 5 | 2015 | 72 | 1.500 |
Why?
|
| Cell Transplantation | 12 | 2018 | 65 | 1.480 |
Why?
|
| Cell Culture Techniques | 19 | 2019 | 177 | 1.470 |
Why?
|
| Guided Tissue Regeneration | 8 | 2020 | 39 | 1.460 |
Why?
|
| Kidney Diseases | 4 | 2018 | 249 | 1.390 |
Why?
|
| Myoblasts | 8 | 2017 | 42 | 1.320 |
Why?
|
| Hydrogels | 13 | 2020 | 127 | 1.300 |
Why?
|
| Urinary Bladder | 17 | 2014 | 320 | 1.300 |
Why?
|
| Humans | 104 | 2020 | 34562 | 1.260 |
Why?
|
| Corrosion Casting | 3 | 2021 | 10 | 1.240 |
Why?
|
| Wound Healing | 8 | 2019 | 190 | 1.210 |
Why?
|
| Cell Differentiation | 26 | 2020 | 485 | 1.200 |
Why?
|
| Bioreactors | 8 | 2015 | 61 | 1.180 |
Why?
|
| Blood Vessel Prosthesis | 10 | 2017 | 87 | 1.170 |
Why?
|
| Cell Survival | 23 | 2020 | 304 | 1.100 |
Why?
|
| Osteogenesis | 9 | 2020 | 81 | 1.070 |
Why?
|
| Neurites | 2 | 2020 | 11 | 1.050 |
Why?
|
| Recovery of Function | 7 | 2020 | 251 | 1.040 |
Why?
|
| Microscopy, Electron, Scanning | 21 | 2020 | 106 | 1.020 |
Why?
|
| Myocytes, Smooth Muscle | 11 | 2017 | 95 | 1.020 |
Why?
|
| Erythropoietin | 3 | 2012 | 33 | 1.020 |
Why?
|
| Disease Models, Animal | 18 | 2020 | 1129 | 1.000 |
Why?
|
| Prostheses and Implants | 3 | 2014 | 53 | 0.990 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2012 | 227 | 0.960 |
Why?
|
| Rats, Nude | 10 | 2020 | 48 | 0.930 |
Why?
|
| Swine | 17 | 2020 | 233 | 0.920 |
Why?
|
| Myoblasts, Skeletal | 4 | 2020 | 21 | 0.910 |
Why?
|
| Kidney Failure, Chronic | 7 | 2015 | 548 | 0.910 |
Why?
|
| Mice, Nude | 19 | 2020 | 296 | 0.890 |
Why?
|
| Nerve Regeneration | 5 | 2013 | 51 | 0.880 |
Why?
|
| Biomimetic Materials | 4 | 2020 | 15 | 0.870 |
Why?
|
| Biomedical Engineering | 4 | 2020 | 28 | 0.860 |
Why?
|
| Male | 59 | 2020 | 20740 | 0.860 |
Why?
|
| Skin | 5 | 2020 | 224 | 0.840 |
Why?
|
| Colonoscopy | 2 | 2015 | 46 | 0.830 |
Why?
|
| Heart Valve Prosthesis | 4 | 2015 | 61 | 0.810 |
Why?
|
| Ear Cartilage | 3 | 2020 | 12 | 0.790 |
Why?
|
| Materials Testing | 11 | 2018 | 93 | 0.790 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2021 | 118 | 0.790 |
Why?
|
| Bioprosthesis | 6 | 2017 | 62 | 0.780 |
Why?
|
| Rabbits | 23 | 2020 | 231 | 0.770 |
Why?
|
| Reconstructive Surgical Procedures | 7 | 2015 | 202 | 0.730 |
Why?
|
| Collagen Type I | 4 | 2013 | 48 | 0.690 |
Why?
|
| Heart Valves | 2 | 2011 | 16 | 0.680 |
Why?
|
| Protein Kinase C | 2 | 2011 | 43 | 0.680 |
Why?
|
| Bone Regeneration | 4 | 2020 | 33 | 0.670 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 2020 | 3 | 0.660 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2020 | 4 | 0.660 |
Why?
|
| Pelvic Floor | 1 | 2020 | 23 | 0.660 |
Why?
|
| Muscular Diseases | 2 | 2020 | 25 | 0.660 |
Why?
|
| Anemia | 2 | 2012 | 58 | 0.640 |
Why?
|
| Urethral Stricture | 5 | 2015 | 31 | 0.640 |
Why?
|
| Culture Media, Conditioned | 3 | 2019 | 53 | 0.640 |
Why?
|
| Cell Communication | 2 | 2019 | 42 | 0.640 |
Why?
|
| Ganglia, Spinal | 1 | 2020 | 72 | 0.630 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 232 | 0.620 |
Why?
|
| Oxygen | 5 | 2015 | 152 | 0.600 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 107 | 0.580 |
Why?
|
| Chondrocytes | 9 | 2018 | 70 | 0.580 |
Why?
|
| Mesenchymal Stem Cells | 6 | 2019 | 183 | 0.580 |
Why?
|
| Neuromuscular Junction | 3 | 2020 | 76 | 0.570 |
Why?
|
| Female | 44 | 2020 | 21532 | 0.560 |
Why?
|
| Neovascularization, Physiologic | 9 | 2021 | 118 | 0.540 |
Why?
|
| Kidney Glomerulus | 1 | 2018 | 30 | 0.540 |
Why?
|
| Mice, Inbred C57BL | 6 | 2019 | 842 | 0.530 |
Why?
|
| Cell Line | 9 | 2019 | 476 | 0.520 |
Why?
|
| Sheep | 10 | 2017 | 233 | 0.520 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2019 | 111 | 0.520 |
Why?
|
| Injections | 4 | 2015 | 76 | 0.510 |
Why?
|
| Adult Stem Cells | 1 | 2017 | 26 | 0.510 |
Why?
|
| Sus scrofa | 6 | 2017 | 49 | 0.490 |
Why?
|
| Receptors, Cholinergic | 3 | 2013 | 26 | 0.490 |
Why?
|
| Social Control, Formal | 1 | 2016 | 4 | 0.480 |
Why?
|
| Biomimetics | 1 | 2016 | 7 | 0.480 |
Why?
|
| Polymers | 10 | 2017 | 71 | 0.480 |
Why?
|
| Chondrogenesis | 2 | 2015 | 20 | 0.480 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2017 | 65 | 0.480 |
Why?
|
| Urinary Incontinence, Stress | 5 | 2017 | 75 | 0.470 |
Why?
|
| Urologic Surgical Procedures | 2 | 2015 | 66 | 0.460 |
Why?
|
| Rats, Inbred Lew | 8 | 2015 | 123 | 0.460 |
Why?
|
| Signal Transduction | 3 | 2020 | 771 | 0.460 |
Why?
|
| Cell Adhesion | 7 | 2012 | 116 | 0.460 |
Why?
|
| Immunocompetence | 1 | 2015 | 12 | 0.460 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 79 | 0.450 |
Why?
|
| Placenta | 3 | 2020 | 76 | 0.430 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2014 | 4 | 0.430 |
Why?
|
| Antigens, CD | 4 | 2018 | 106 | 0.430 |
Why?
|
| Erectile Dysfunction | 4 | 2020 | 71 | 0.430 |
Why?
|
| Tendons | 2 | 2013 | 61 | 0.420 |
Why?
|
| Cyclooxygenase 2 | 2 | 2012 | 51 | 0.420 |
Why?
|
| Ink | 4 | 2019 | 11 | 0.420 |
Why?
|
| Ear Auricle | 1 | 2014 | 5 | 0.420 |
Why?
|
| Immunohistochemistry | 15 | 2017 | 600 | 0.410 |
Why?
|
| Penis | 7 | 2012 | 45 | 0.410 |
Why?
|
| Lactic Acid | 8 | 2016 | 59 | 0.410 |
Why?
|
| Down-Regulation | 1 | 2014 | 145 | 0.410 |
Why?
|
| Polyglycolic Acid | 10 | 2016 | 33 | 0.410 |
Why?
|
| Hernia, Abdominal | 2 | 2011 | 9 | 0.410 |
Why?
|
| Cytological Techniques | 1 | 2013 | 17 | 0.400 |
Why?
|
| Polyglactin 910 | 2 | 2019 | 6 | 0.400 |
Why?
|
| Time Factors | 10 | 2020 | 2353 | 0.390 |
Why?
|
| Cell Separation | 5 | 2016 | 93 | 0.390 |
Why?
|
| Culture Media | 2 | 2012 | 50 | 0.390 |
Why?
|
| Colonic Polyps | 1 | 2013 | 17 | 0.390 |
Why?
|
| Transfection | 3 | 2012 | 216 | 0.380 |
Why?
|
| Gene Transfer Techniques | 5 | 2012 | 66 | 0.380 |
Why?
|
| Tissue Culture Techniques | 3 | 2010 | 44 | 0.380 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2013 | 45 | 0.380 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 13 | 0.370 |
Why?
|
| Jugular Veins | 1 | 2012 | 27 | 0.370 |
Why?
|
| Mucous Membrane | 4 | 2013 | 28 | 0.370 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 58 | 0.370 |
Why?
|
| Carotid Arteries | 1 | 2012 | 116 | 0.360 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2012 | 48 | 0.360 |
Why?
|
| Muscle Contraction | 5 | 2008 | 183 | 0.360 |
Why?
|
| Muscles | 1 | 2012 | 69 | 0.360 |
Why?
|
| Neurosurgical Procedures | 1 | 2012 | 101 | 0.360 |
Why?
|
| Peripheral Nerves | 1 | 2012 | 65 | 0.360 |
Why?
|
| Cell Movement | 5 | 2019 | 182 | 0.360 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2011 | 5 | 0.350 |
Why?
|
| Bradykinin | 1 | 2011 | 12 | 0.350 |
Why?
|
| Hemodynamics | 1 | 2012 | 168 | 0.350 |
Why?
|
| Pregnancy | 8 | 2020 | 1069 | 0.350 |
Why?
|
| Nanostructures | 2 | 2008 | 21 | 0.340 |
Why?
|
| Blotting, Western | 9 | 2014 | 328 | 0.340 |
Why?
|
| Stress, Mechanical | 5 | 2015 | 102 | 0.340 |
Why?
|
| Fibroblasts | 4 | 2020 | 122 | 0.340 |
Why?
|
| Feasibility Studies | 9 | 2020 | 323 | 0.340 |
Why?
|
| Bioartificial Organs | 4 | 2016 | 26 | 0.330 |
Why?
|
| Lysophospholipids | 1 | 2011 | 27 | 0.330 |
Why?
|
| Laparoscopy | 1 | 2013 | 194 | 0.330 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 515 | 0.330 |
Why?
|
| Dermis | 1 | 2010 | 18 | 0.320 |
Why?
|
| Endothelium, Vascular | 4 | 2016 | 163 | 0.320 |
Why?
|
| Oxidative Stress | 1 | 2012 | 265 | 0.320 |
Why?
|
| Equipment Design | 5 | 2019 | 192 | 0.320 |
Why?
|
| Abdominal Wall | 1 | 2010 | 24 | 0.320 |
Why?
|
| Cattle | 9 | 2015 | 118 | 0.320 |
Why?
|
| Inflammation | 3 | 2012 | 557 | 0.320 |
Why?
|
| Osteoblasts | 2 | 2010 | 44 | 0.320 |
Why?
|
| Renal Dialysis | 1 | 2012 | 282 | 0.310 |
Why?
|
| Glycoproteins | 3 | 2015 | 44 | 0.300 |
Why?
|
| Apoptosis | 4 | 2019 | 400 | 0.300 |
Why?
|
| Clinical Medicine | 1 | 2009 | 13 | 0.300 |
Why?
|
| Foreskin | 1 | 2009 | 8 | 0.300 |
Why?
|
| Urinary Incontinence | 3 | 2015 | 68 | 0.300 |
Why?
|
| Flow Cytometry | 7 | 2016 | 198 | 0.290 |
Why?
|
| Peptides | 3 | 2015 | 143 | 0.290 |
Why?
|
| Granulosa Cells | 2 | 2019 | 11 | 0.290 |
Why?
|
| Delayed-Action Preparations | 2 | 2012 | 36 | 0.290 |
Why?
|
| Transplantation | 1 | 2008 | 13 | 0.280 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2017 | 62 | 0.280 |
Why?
|
| Kidney Cortex | 1 | 2008 | 25 | 0.280 |
Why?
|
| Tensile Strength | 9 | 2017 | 60 | 0.280 |
Why?
|
| MyoD Protein | 3 | 2014 | 10 | 0.280 |
Why?
|
| Rats, Sprague-Dawley | 10 | 2019 | 923 | 0.280 |
Why?
|
| Urology | 1 | 2008 | 33 | 0.270 |
Why?
|
| Testosterone | 1 | 2008 | 51 | 0.270 |
Why?
|
| Hormone Replacement Therapy | 2 | 2019 | 96 | 0.270 |
Why?
|
| Pluripotent Stem Cells | 3 | 2015 | 18 | 0.270 |
Why?
|
| Testis | 1 | 2008 | 72 | 0.270 |
Why?
|
| Muscle, Smooth | 7 | 2012 | 152 | 0.270 |
Why?
|
| Agrin | 2 | 2020 | 9 | 0.270 |
Why?
|
| Cell Hypoxia | 3 | 2019 | 43 | 0.260 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2019 | 83 | 0.260 |
Why?
|
| Implants, Experimental | 4 | 2019 | 13 | 0.260 |
Why?
|
| Biological Factors | 1 | 2007 | 11 | 0.260 |
Why?
|
| Chick Embryo | 2 | 2020 | 76 | 0.260 |
Why?
|
| Biomedical Research | 1 | 2009 | 186 | 0.260 |
Why?
|
| Prosthesis Implantation | 5 | 2016 | 41 | 0.260 |
Why?
|
| Uterus | 4 | 2020 | 106 | 0.250 |
Why?
|
| Skin Transplantation | 3 | 2017 | 50 | 0.250 |
Why?
|
| Cartilage | 3 | 2015 | 33 | 0.250 |
Why?
|
| Neurons | 2 | 2020 | 491 | 0.240 |
Why?
|
| Bioengineering | 3 | 2015 | 77 | 0.230 |
Why?
|
| Actins | 6 | 2015 | 56 | 0.230 |
Why?
|
| Trachea | 2 | 2016 | 56 | 0.230 |
Why?
|
| Dogs | 8 | 2015 | 130 | 0.230 |
Why?
|
| Alkaline Phosphatase | 3 | 2019 | 44 | 0.220 |
Why?
|
| Ovary | 2 | 2017 | 69 | 0.220 |
Why?
|
| Gels | 2 | 2019 | 33 | 0.220 |
Why?
|
| Gelatin | 4 | 2019 | 29 | 0.220 |
Why?
|
| Surgical Flaps | 2 | 2015 | 78 | 0.220 |
Why?
|
| Fetal Stem Cells | 2 | 2015 | 10 | 0.220 |
Why?
|
| Vagina | 3 | 2014 | 61 | 0.220 |
Why?
|
| Cytokines | 4 | 2019 | 269 | 0.220 |
Why?
|
| NIH 3T3 Cells | 5 | 2012 | 45 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2019 | 281 | 0.210 |
Why?
|
| Spheroids, Cellular | 3 | 2019 | 39 | 0.210 |
Why?
|
| Transplantation, Autologous | 6 | 2016 | 104 | 0.210 |
Why?
|
| Organ Transplantation | 2 | 2017 | 67 | 0.200 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2012 | 103 | 0.200 |
Why?
|
| Cells, Immobilized | 2 | 2014 | 22 | 0.190 |
Why?
|
| Models, Animal | 6 | 2017 | 198 | 0.190 |
Why?
|
| Calcium | 3 | 2017 | 343 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2018 | 3623 | 0.190 |
Why?
|
| Cryoprotective Agents | 2 | 2014 | 10 | 0.190 |
Why?
|
| Muscle Denervation | 2 | 2013 | 31 | 0.190 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 2 | 2012 | 6 | 0.190 |
Why?
|
| Starch | 2 | 2012 | 8 | 0.190 |
Why?
|
| Theca Cells | 2 | 2019 | 9 | 0.190 |
Why?
|
| Keratinocytes | 2 | 2020 | 30 | 0.190 |
Why?
|
| Urethral Diseases | 2 | 2014 | 20 | 0.180 |
Why?
|
| Liver | 3 | 2017 | 513 | 0.180 |
Why?
|
| Transplantation, Heterologous | 4 | 2012 | 123 | 0.180 |
Why?
|
| Porosity | 5 | 2016 | 41 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 988 | 0.180 |
Why?
|
| Muscle Development | 5 | 2019 | 53 | 0.180 |
Why?
|
| Cell Count | 3 | 2017 | 55 | 0.180 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2012 | 17 | 0.180 |
Why?
|
| Middle Aged | 7 | 2016 | 12726 | 0.180 |
Why?
|
| Urodynamics | 6 | 2013 | 88 | 0.180 |
Why?
|
| Myocytes, Cardiac | 2 | 2018 | 97 | 0.180 |
Why?
|
| Alginates | 2 | 2018 | 52 | 0.170 |
Why?
|
| Skin, Artificial | 2 | 2019 | 34 | 0.170 |
Why?
|
| Estrogens | 2 | 2019 | 210 | 0.170 |
Why?
|
| Rheology | 5 | 2019 | 35 | 0.170 |
Why?
|
| Plasmids | 2 | 2012 | 52 | 0.170 |
Why?
|
| Cell-Free System | 3 | 2015 | 16 | 0.160 |
Why?
|
| Neurogenesis | 1 | 2020 | 17 | 0.160 |
Why?
|
| Live Birth | 1 | 2020 | 7 | 0.160 |
Why?
|
| Urothelium | 3 | 2016 | 67 | 0.160 |
Why?
|
| Terminology as Topic | 2 | 2017 | 71 | 0.160 |
Why?
|
| Trauma, Nervous System | 1 | 2020 | 9 | 0.160 |
Why?
|
| Cicatrix | 3 | 2017 | 41 | 0.160 |
Why?
|
| Luciferases | 1 | 2019 | 35 | 0.150 |
Why?
|
| Nanofibers | 1 | 2019 | 7 | 0.150 |
Why?
|
| Wounds and Injuries | 3 | 2019 | 248 | 0.150 |
Why?
|
| Penile Prosthesis | 4 | 2009 | 19 | 0.150 |
Why?
|
| Equipment Failure Analysis | 3 | 2016 | 47 | 0.150 |
Why?
|
| Prosthesis Design | 4 | 2015 | 116 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 180 | 0.150 |
Why?
|
| Podocytes | 1 | 2019 | 20 | 0.150 |
Why?
|
| Platelet-Rich Plasma | 1 | 2019 | 12 | 0.150 |
Why?
|
| Adult | 8 | 2016 | 10030 | 0.150 |
Why?
|
| Tissue Transplantation | 1 | 2019 | 17 | 0.150 |
Why?
|
| Pilot Projects | 4 | 2016 | 585 | 0.150 |
Why?
|
| Phenotype | 7 | 2016 | 657 | 0.150 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2019 | 28 | 0.150 |
Why?
|
| Parthenogenesis | 2 | 2009 | 7 | 0.150 |
Why?
|
| Stromal Cells | 1 | 2019 | 86 | 0.150 |
Why?
|
| Sciatic Nerve | 2 | 2012 | 39 | 0.140 |
Why?
|
| Aged | 4 | 2016 | 11022 | 0.140 |
Why?
|
| Urinary Bladder, Neurogenic | 3 | 2010 | 30 | 0.140 |
Why?
|
| Elastic Modulus | 3 | 2016 | 29 | 0.140 |
Why?
|
| Vascular Patency | 3 | 2014 | 71 | 0.140 |
Why?
|
| Cystoscopy | 3 | 2014 | 28 | 0.140 |
Why?
|
| Fibroins | 1 | 2018 | 5 | 0.140 |
Why?
|
| Mandible | 2 | 2016 | 39 | 0.140 |
Why?
|
| Graft Survival | 3 | 2017 | 315 | 0.140 |
Why?
|
| Tissue Donors | 1 | 2019 | 208 | 0.140 |
Why?
|
| Peroxides | 2 | 2015 | 32 | 0.130 |
Why?
|
| Myocardial Contraction | 1 | 2018 | 66 | 0.130 |
Why?
|
| Kinetics | 3 | 2019 | 259 | 0.130 |
Why?
|
| Vimentin | 2 | 2015 | 11 | 0.130 |
Why?
|
| Intracellular Space | 2 | 2014 | 18 | 0.130 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 36 | 0.130 |
Why?
|
| Ischemia | 2 | 2020 | 119 | 0.130 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2017 | 30 | 0.130 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 18 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2011 | 24 | 0.130 |
Why?
|
| Polyurethanes | 1 | 2016 | 5 | 0.130 |
Why?
|
| Amino Acid Chloromethyl Ketones | 2 | 2014 | 6 | 0.130 |
Why?
|
| Myocardium | 1 | 2018 | 199 | 0.130 |
Why?
|
| Organ Specificity | 2 | 2017 | 86 | 0.130 |
Why?
|
| Infertility, Female | 1 | 2017 | 38 | 0.120 |
Why?
|
| Rats, Inbred F344 | 4 | 2019 | 153 | 0.120 |
Why?
|
| Adolescent | 6 | 2016 | 3805 | 0.120 |
Why?
|
| Ovarian Follicle | 1 | 2016 | 37 | 0.120 |
Why?
|
| Liver Transplantation | 2 | 2014 | 186 | 0.120 |
Why?
|
| Salivary Glands | 2 | 2007 | 14 | 0.120 |
Why?
|
| Burns | 1 | 2017 | 103 | 0.120 |
Why?
|
| Perfusion | 2 | 2015 | 78 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 5 | 2019 | 99 | 0.120 |
Why?
|
| Albumins | 2 | 2015 | 47 | 0.120 |
Why?
|
| Transplants | 1 | 2015 | 24 | 0.120 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 53 | 0.120 |
Why?
|
| Soft Tissue Injuries | 1 | 2015 | 20 | 0.120 |
Why?
|
| Bandages | 1 | 2015 | 34 | 0.120 |
Why?
|
| Anastomosis, Surgical | 1 | 2015 | 60 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2014 | 137 | 0.120 |
Why?
|
| Electrophysiological Phenomena | 2 | 2012 | 31 | 0.120 |
Why?
|
| Pulsatile Flow | 2 | 2012 | 25 | 0.120 |
Why?
|
| Pulmonary Valve | 1 | 2015 | 12 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 170 | 0.110 |
Why?
|
| Bladder Exstrophy | 2 | 2007 | 9 | 0.110 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 526 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 59 | 0.110 |
Why?
|
| Water Supply | 1 | 2015 | 10 | 0.110 |
Why?
|
| RNA | 1 | 2015 | 100 | 0.110 |
Why?
|
| Staining and Labeling | 2 | 2012 | 66 | 0.110 |
Why?
|
| Biological Specimen Banks | 1 | 2015 | 11 | 0.110 |
Why?
|
| Drug Delivery Systems | 2 | 2013 | 112 | 0.110 |
Why?
|
| Drug Industry | 1 | 2015 | 18 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 118 | 0.110 |
Why?
|
| Adipogenesis | 2 | 2020 | 30 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 75 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2013 | 264 | 0.110 |
Why?
|
| Myogenic Regulatory Factor 5 | 1 | 2014 | 7 | 0.110 |
Why?
|
| Gene Knock-In Techniques | 1 | 2014 | 9 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2014 | 5 | 0.110 |
Why?
|
| Biological Products | 1 | 2016 | 80 | 0.110 |
Why?
|
| Cryopreservation | 2 | 2014 | 55 | 0.110 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2014 | 8 | 0.110 |
Why?
|
| Masks | 1 | 2014 | 5 | 0.110 |
Why?
|
| Mullerian Ducts | 1 | 2014 | 3 | 0.110 |
Why?
|
| Facial Injuries | 1 | 2014 | 12 | 0.110 |
Why?
|
| Adipocytes | 2 | 2013 | 85 | 0.110 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 11 | 0.100 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 75 | 0.100 |
Why?
|
| Prostatectomy | 2 | 2020 | 85 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 165 | 0.100 |
Why?
|
| Adenosine | 1 | 2014 | 74 | 0.100 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2014 | 38 | 0.100 |
Why?
|
| Tissue Survival | 2 | 2015 | 13 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2012 | 204 | 0.100 |
Why?
|
| Electric Stimulation | 3 | 2008 | 139 | 0.100 |
Why?
|
| Endoscopy | 1 | 2014 | 56 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 271 | 0.100 |
Why?
|
| Oocytes | 2 | 2016 | 48 | 0.100 |
Why?
|
| Action Potentials | 1 | 2014 | 220 | 0.100 |
Why?
|
| Silk | 1 | 2013 | 3 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2013 | 77 | 0.100 |
Why?
|
| Gonadotropins | 1 | 2012 | 7 | 0.100 |
Why?
|
| Peptide Hormones | 1 | 2012 | 11 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2012 | 14 | 0.100 |
Why?
|
| Homeostasis | 1 | 2013 | 137 | 0.100 |
Why?
|
| Saccule and Utricle | 1 | 2012 | 3 | 0.100 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 28 | 0.100 |
Why?
|
| Printing | 1 | 2012 | 5 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 2 | 2012 | 72 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2012 | 6 | 0.090 |
Why?
|
| Acetylcholine | 1 | 2013 | 69 | 0.090 |
Why?
|
| Genotype | 1 | 2014 | 744 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 29 | 0.090 |
Why?
|
| Steroids | 1 | 2012 | 39 | 0.090 |
Why?
|
| Peroneal Nerve | 1 | 2012 | 15 | 0.090 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2012 | 19 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 1 | 2012 | 43 | 0.090 |
Why?
|
| Calcification, Physiologic | 1 | 2012 | 8 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2012 | 19 | 0.090 |
Why?
|
| Trans-Activators | 1 | 2012 | 45 | 0.090 |
Why?
|
| Axons | 1 | 2012 | 36 | 0.090 |
Why?
|
| Detergents | 1 | 2012 | 18 | 0.090 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 25 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2012 | 9 | 0.090 |
Why?
|
| Punctures | 1 | 2012 | 35 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 47 | 0.090 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2012 | 6 | 0.090 |
Why?
|
| Needles | 1 | 2012 | 33 | 0.090 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 95 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 55 | 0.090 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2012 | 3 | 0.090 |
Why?
|
| Anthraquinones | 1 | 2012 | 5 | 0.090 |
Why?
|
| Neurofilament Proteins | 1 | 2012 | 18 | 0.090 |
Why?
|
| Aggrecans | 1 | 2012 | 4 | 0.090 |
Why?
|
| Collagen Type II | 1 | 2012 | 8 | 0.090 |
Why?
|
| Sepharose | 1 | 2012 | 6 | 0.090 |
Why?
|
| Cell Death | 1 | 2012 | 85 | 0.090 |
Why?
|
| Parkinson Disease | 1 | 2013 | 92 | 0.090 |
Why?
|
| Quantum Dots | 1 | 2012 | 1 | 0.090 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 58 | 0.090 |
Why?
|
| Absorption | 1 | 2012 | 16 | 0.090 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2012 | 11 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 36 | 0.090 |
Why?
|
| Muscle, Striated | 1 | 2012 | 4 | 0.090 |
Why?
|
| Kidney Tubules | 1 | 2012 | 26 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 38 | 0.090 |
Why?
|
| Epidermal Growth Factor | 1 | 2012 | 31 | 0.090 |
Why?
|
| Ankle Joint | 1 | 2012 | 51 | 0.090 |
Why?
|
| Myosin Heavy Chains | 2 | 2011 | 89 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 44 | 0.090 |
Why?
|
| Proteins | 1 | 2013 | 155 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2012 | 148 | 0.090 |
Why?
|
| Substance P | 1 | 2011 | 23 | 0.090 |
Why?
|
| Maleimides | 1 | 2011 | 8 | 0.090 |
Why?
|
| Butadienes | 1 | 2011 | 9 | 0.090 |
Why?
|
| Immunity | 1 | 2011 | 22 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2011 | 29 | 0.090 |
Why?
|
| Nitriles | 1 | 2011 | 26 | 0.090 |
Why?
|
| Microscopy, Confocal | 3 | 2019 | 80 | 0.090 |
Why?
|
| Length of Stay | 1 | 2013 | 335 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 81 | 0.090 |
Why?
|
| General Surgery | 1 | 2012 | 85 | 0.090 |
Why?
|
| Indoles | 1 | 2011 | 67 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 590 | 0.080 |
Why?
|
| Pertussis Toxin | 1 | 2011 | 19 | 0.080 |
Why?
|
| Isoxazoles | 1 | 2011 | 7 | 0.080 |
Why?
|
| Propionates | 1 | 2011 | 8 | 0.080 |
Why?
|
| Meningomyelocele | 2 | 2008 | 10 | 0.080 |
Why?
|
| Quinazolinones | 1 | 2011 | 7 | 0.080 |
Why?
|
| Thrombin | 1 | 2010 | 26 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2011 | 37 | 0.080 |
Why?
|
| Cystitis | 1 | 2010 | 8 | 0.080 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2010 | 15 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 755 | 0.080 |
Why?
|
| Fibrinogen | 1 | 2010 | 69 | 0.080 |
Why?
|
| Lymphocytes | 1 | 2011 | 59 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 152 | 0.080 |
Why?
|
| Hepatocytes | 1 | 2011 | 84 | 0.080 |
Why?
|
| Genetic Vectors | 3 | 2013 | 127 | 0.080 |
Why?
|
| Insulin | 1 | 2012 | 394 | 0.080 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2010 | 38 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 94 | 0.080 |
Why?
|
| Umbilical Veins | 1 | 2010 | 15 | 0.080 |
Why?
|
| Hernia | 1 | 2010 | 11 | 0.080 |
Why?
|
| Behavior, Animal | 1 | 2012 | 303 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 175 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2012 | 545 | 0.080 |
Why?
|
| Piperidines | 1 | 2011 | 141 | 0.080 |
Why?
|
| Random Allocation | 1 | 2010 | 257 | 0.080 |
Why?
|
| Elastin | 2 | 2008 | 17 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 1 | 2009 | 18 | 0.080 |
Why?
|
| Chromatography, Affinity | 1 | 2009 | 17 | 0.080 |
Why?
|
| Hematology | 1 | 2009 | 9 | 0.080 |
Why?
|
| Mice, Inbred ICR | 3 | 2014 | 12 | 0.070 |
Why?
|
| Fibrosis | 3 | 2020 | 131 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2019 | 196 | 0.070 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2009 | 14 | 0.070 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2008 | 7 | 0.070 |
Why?
|
| Sexual Behavior, Animal | 1 | 2008 | 11 | 0.070 |
Why?
|
| Electroporation | 1 | 2009 | 15 | 0.070 |
Why?
|
| Kidney Tubules, Distal | 1 | 2008 | 3 | 0.070 |
Why?
|
| Loop of Henle | 1 | 2008 | 4 | 0.070 |
Why?
|
| Desmin | 1 | 2008 | 12 | 0.070 |
Why?
|
| Platelet Adhesiveness | 1 | 2008 | 22 | 0.070 |
Why?
|
| Liposomes | 1 | 2009 | 34 | 0.070 |
Why?
|
| Mucoproteins | 1 | 2008 | 13 | 0.070 |
Why?
|
| Myosins | 2 | 2012 | 12 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2009 | 95 | 0.070 |
Why?
|
| Multipotent Stem Cells | 1 | 2008 | 17 | 0.070 |
Why?
|
| X-Ray Microtomography | 3 | 2015 | 45 | 0.070 |
Why?
|
| Organ Preservation Solutions | 1 | 2008 | 8 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 781 | 0.070 |
Why?
|
| Orchiectomy | 1 | 2008 | 14 | 0.070 |
Why?
|
| Scrotum | 1 | 2008 | 7 | 0.070 |
Why?
|
| Immunophenotyping | 1 | 2008 | 51 | 0.070 |
Why?
|
| Cell Lineage | 3 | 2013 | 71 | 0.070 |
Why?
|
| Aorta | 1 | 2009 | 139 | 0.070 |
Why?
|
| Muscle Relaxation | 1 | 2008 | 21 | 0.070 |
Why?
|
| Adenoviridae | 2 | 2012 | 69 | 0.070 |
Why?
|
| Penile Erection | 3 | 2020 | 33 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2012 | 901 | 0.070 |
Why?
|
| Urine | 1 | 2008 | 70 | 0.070 |
Why?
|
| Microfluidics | 2 | 2017 | 18 | 0.070 |
Why?
|
| Progesterone | 2 | 2019 | 112 | 0.070 |
Why?
|
| Viscosity | 2 | 2018 | 26 | 0.070 |
Why?
|
| DNA | 3 | 2017 | 235 | 0.070 |
Why?
|
| Elasticity | 2 | 2018 | 43 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2010 | 366 | 0.070 |
Why?
|
| Cartilage, Articular | 1 | 2008 | 78 | 0.070 |
Why?
|
| United States | 1 | 2016 | 4278 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2019 | 87 | 0.060 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 35 | 0.060 |
Why?
|
| Urinary Bladder Diseases | 1 | 2006 | 45 | 0.060 |
Why?
|
| Glycolates | 1 | 2005 | 7 | 0.060 |
Why?
|
| Compressive Strength | 2 | 2016 | 23 | 0.060 |
Why?
|
| Bone and Bones | 2 | 2019 | 99 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 4157 | 0.060 |
Why?
|
| Heparin | 2 | 2017 | 74 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2013 | 3825 | 0.050 |
Why?
|
| Gene Expression | 3 | 2015 | 363 | 0.050 |
Why?
|
| Organ Culture Techniques | 2 | 2015 | 44 | 0.050 |
Why?
|
| Muscle Cells | 1 | 2003 | 7 | 0.050 |
Why?
|
| DNA Repair | 1 | 2003 | 57 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2003 | 79 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 86 | 0.050 |
Why?
|
| DNA Damage | 1 | 2003 | 97 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 70 | 0.050 |
Why?
|
| Hypospadias | 1 | 2002 | 10 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2008 | 837 | 0.050 |
Why?
|
| Histocompatibility | 1 | 2002 | 7 | 0.050 |
Why?
|
| Nuclear Transfer Techniques | 1 | 2002 | 9 | 0.050 |
Why?
|
| Cloning, Organism | 1 | 2002 | 12 | 0.050 |
Why?
|
| Cytoskeleton | 2 | 2013 | 20 | 0.050 |
Why?
|
| Biological Transport | 2 | 2012 | 76 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2012 | 87 | 0.040 |
Why?
|
| Organoids | 2 | 2017 | 99 | 0.040 |
Why?
|
| Child | 4 | 2011 | 2614 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2012 | 508 | 0.040 |
Why?
|
| Hypogastric Plexus | 1 | 2020 | 8 | 0.040 |
Why?
|
| Fetus | 1 | 2020 | 91 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 96 | 0.040 |
Why?
|
| Aromatase | 1 | 2019 | 12 | 0.040 |
Why?
|
| Luteinizing Hormone | 1 | 2019 | 24 | 0.040 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2019 | 31 | 0.040 |
Why?
|
| Cues | 1 | 2019 | 65 | 0.040 |
Why?
|
| Pelvis | 1 | 2020 | 69 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2019 | 22 | 0.040 |
Why?
|
| Methacrylates | 1 | 2019 | 3 | 0.040 |
Why?
|
| Clone Cells | 2 | 2011 | 37 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 52 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 2011 | 57 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2019 | 204 | 0.040 |
Why?
|
| Nerve Net | 1 | 2020 | 141 | 0.040 |
Why?
|
| Vesico-Ureteral Reflux | 2 | 2008 | 22 | 0.040 |
Why?
|
| Light | 1 | 2018 | 42 | 0.030 |
Why?
|
| Strontium | 1 | 2017 | 5 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2017 | 10 | 0.030 |
Why?
|
| Hormones | 1 | 2017 | 26 | 0.030 |
Why?
|
| Tissue Expansion Devices | 1 | 2017 | 12 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 38 | 0.030 |
Why?
|
| Administration, Intravesical | 2 | 2010 | 28 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2008 | 850 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2017 | 54 | 0.030 |
Why?
|
| Meiosis | 1 | 2016 | 33 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 279 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 56 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 341 | 0.030 |
Why?
|
| Thermal Conductivity | 1 | 2016 | 2 | 0.030 |
Why?
|
| Transition Temperature | 1 | 2016 | 5 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 234 | 0.030 |
Why?
|
| Heart | 1 | 2017 | 191 | 0.030 |
Why?
|
| Bone Density | 1 | 2017 | 209 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2016 | 56 | 0.030 |
Why?
|
| Myostatin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2015 | 9 | 0.030 |
Why?
|
| Estradiol | 1 | 2016 | 156 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 29 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 65 | 0.030 |
Why?
|
| Antigens, Differentiation | 1 | 2015 | 27 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2008 | 926 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 79 | 0.030 |
Why?
|
| Solutions | 1 | 2015 | 41 | 0.030 |
Why?
|
| Lung | 1 | 2017 | 279 | 0.030 |
Why?
|
| Urea | 1 | 2015 | 39 | 0.030 |
Why?
|
| Hardness | 1 | 2015 | 5 | 0.030 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2015 | 37 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 326 | 0.030 |
Why?
|
| beta Catenin | 1 | 2015 | 39 | 0.030 |
Why?
|
| Muscular Atrophy | 1 | 2015 | 77 | 0.030 |
Why?
|
| Arizona | 1 | 2015 | 8 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 67 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2015 | 146 | 0.030 |
Why?
|
| Polymethyl Methacrylate | 1 | 2015 | 13 | 0.030 |
Why?
|
| beta-Galactosidase | 2 | 2005 | 20 | 0.030 |
Why?
|
| PAX7 Transcription Factor | 1 | 2014 | 10 | 0.030 |
Why?
|
| Echocardiography | 1 | 2015 | 202 | 0.030 |
Why?
|
| Keratins | 2 | 2005 | 42 | 0.030 |
Why?
|
| Tenascin | 1 | 2013 | 5 | 0.030 |
Why?
|
| Collagen Type III | 1 | 2013 | 9 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 146 | 0.030 |
Why?
|
| Protein Transport | 1 | 2013 | 82 | 0.030 |
Why?
|
| Glycogen | 1 | 2013 | 3 | 0.030 |
Why?
|
| Oxidopamine | 1 | 2013 | 24 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2013 | 34 | 0.030 |
Why?
|
| Substantia Nigra | 1 | 2013 | 20 | 0.030 |
Why?
|
| Tendon Injuries | 1 | 2013 | 40 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 45 | 0.030 |
Why?
|
| Urination | 1 | 2014 | 69 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2015 | 197 | 0.020 |
Why?
|
| Software | 1 | 2014 | 130 | 0.020 |
Why?
|
| Poloxamer | 1 | 2013 | 4 | 0.020 |
Why?
|
| Myoglobin | 1 | 2013 | 11 | 0.020 |
Why?
|
| Endocrine Cells | 1 | 2012 | 3 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 12 | 0.020 |
Why?
|
| Lentivirus | 1 | 2013 | 11 | 0.020 |
Why?
|
| Diffusion | 1 | 2012 | 17 | 0.020 |
Why?
|
| Culture Techniques | 2 | 2003 | 14 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2012 | 36 | 0.020 |
Why?
|
| Hair Cells, Auditory | 1 | 2012 | 4 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2012 | 16 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 46 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2012 | 20 | 0.020 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2012 | 18 | 0.020 |
Why?
|
| S Phase | 1 | 2012 | 15 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2012 | 18 | 0.020 |
Why?
|
| Mitosis | 1 | 2012 | 26 | 0.020 |
Why?
|
| C-Peptide | 1 | 2012 | 33 | 0.020 |
Why?
|
| Fibrin | 1 | 2012 | 33 | 0.020 |
Why?
|
| Isometric Contraction | 2 | 2002 | 28 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2012 | 35 | 0.020 |
Why?
|
| CHO Cells | 1 | 2012 | 29 | 0.020 |
Why?
|
| Ganciclovir | 1 | 2012 | 23 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2012 | 35 | 0.020 |
Why?
|
| Cricetinae | 1 | 2012 | 52 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2012 | 23 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 203 | 0.020 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 56 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 74 | 0.020 |
Why?
|
| Hela Cells | 1 | 2012 | 82 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 63 | 0.020 |
Why?
|
| Transgenes | 1 | 2012 | 52 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 47 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2012 | 49 | 0.020 |
Why?
|
| Larynx | 1 | 2012 | 21 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 2012 | 23 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 39 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2012 | 41 | 0.020 |
Why?
|
| Tissue Banks | 1 | 2011 | 15 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2006 | 1355 | 0.020 |
Why?
|
| Immunochemistry | 1 | 2011 | 8 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 561 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2011 | 23 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 35 | 0.020 |
Why?
|
| Developmental Biology | 1 | 2011 | 6 | 0.020 |
Why?
|
| Trehalose | 1 | 2011 | 3 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2011 | 76 | 0.020 |
Why?
|
| Catalase | 1 | 2011 | 16 | 0.020 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2011 | 13 | 0.020 |
Why?
|
| Mexico | 1 | 2011 | 72 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2011 | 31 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2011 | 96 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2010 | 18 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2011 | 46 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 25 | 0.020 |
Why?
|
| Carotid Artery, Common | 1 | 2011 | 49 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2011 | 50 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 165 | 0.020 |
Why?
|
| Calcium Phosphates | 1 | 2010 | 9 | 0.020 |
Why?
|
| Infant | 2 | 2005 | 1123 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2011 | 65 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 38 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 532 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2010 | 13 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 21 | 0.020 |
Why?
|
| Electrochemical Techniques | 1 | 2010 | 26 | 0.020 |
Why?
|
| Azacitidine | 1 | 2010 | 29 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 22 | 0.020 |
Why?
|
| Copulation | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 1910 | 0.020 |
Why?
|
| Stents | 1 | 2011 | 167 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 110 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 439 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 5 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2008 | 45 | 0.020 |
Why?
|
| Vaginal Diseases | 1 | 2008 | 7 | 0.020 |
Why?
|
| Femoral Nerve | 1 | 2008 | 8 | 0.020 |
Why?
|
| Ureteral Obstruction | 1 | 2008 | 28 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2008 | 12 | 0.020 |
Why?
|
| Electrolytes | 1 | 2008 | 11 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2008 | 21 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2008 | 29 | 0.020 |
Why?
|
| Urinalysis | 1 | 2008 | 27 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2008 | 30 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 47 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 265 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 823 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1393 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 273 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2007 | 12 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 38 | 0.020 |
Why?
|
| Cystectomy | 1 | 2008 | 110 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 614 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2008 | 549 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 397 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2006 | 104 | 0.010 |
Why?
|
| Shear Strength | 1 | 2005 | 10 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2367 | 0.010 |
Why?
|
| Genetic Enhancement | 1 | 2005 | 4 | 0.010 |
Why?
|
| Circumcision, Male | 1 | 2005 | 4 | 0.010 |
Why?
|
| Protein Engineering | 1 | 2005 | 19 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 92 | 0.010 |
Why?
|
| Aquaporin 5 | 1 | 2005 | 4 | 0.010 |
Why?
|
| Biodegradation, Environmental | 1 | 2005 | 4 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 99 | 0.010 |
Why?
|
| Aquaporins | 1 | 2005 | 5 | 0.010 |
Why?
|
| alpha-Amylases | 1 | 2005 | 4 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2007 | 730 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2005 | 132 | 0.010 |
Why?
|
| Heart Failure | 1 | 2012 | 780 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 265 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 281 | 0.010 |
Why?
|
| Nerve Growth Factor | 1 | 2004 | 5 | 0.010 |
Why?
|
| Ploidies | 1 | 2003 | 7 | 0.010 |
Why?
|
| G1 Phase | 1 | 2003 | 10 | 0.010 |
Why?
|
| G2 Phase | 1 | 2003 | 17 | 0.010 |
Why?
|
| Nerve Endings | 1 | 2003 | 4 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 34 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 268 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 2003 | 69 | 0.010 |
Why?
|
| Receptors, Adrenergic | 1 | 2002 | 13 | 0.010 |
Why?
|
| Hydrochloric Acid | 1 | 2002 | 4 | 0.010 |
Why?
|
| Lac Operon | 1 | 2002 | 7 | 0.010 |
Why?
|
| Receptors, Muscarinic | 1 | 2002 | 21 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2002 | 11 | 0.010 |
Why?
|
| Glycosaminoglycans | 1 | 2002 | 23 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2002 | 80 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2002 | 113 | 0.010 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2002 | 19 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2003 | 148 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2002 | 92 | 0.010 |
Why?
|